S-1: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

Summary

• Aptevo Therapeutics Inc. is undertaking a public offering of up to 6,024,096 shares of common stock, along with common warrants to purchase up to 12,048,192 shares.
• Pre-funded warrants are also being offered to certain purchasers as an alternative to common stock, along with the same common warrants.
• The assumed combined public offering price is $0.83 per share and common warrant, based on the last reported sale price on June 10, 2024.
• The common warrants will be exercisable upon Stockholder Approval at an exercise price of $ per share and will expire five years from the date of Stockholder Approval.
• The pre-funded warrants will have an exercise price of $0.0001 per share and are exercisable upon issuance, expiring when exercised in full.
• Roth Capital Partners, LLC is acting as the exclusive placement agent, with Dawson James Securities, Inc. as co-agent.
• The offering will terminate no later than July 12, 2024, unless terminated earlier by the company.
• The company intends to use the net proceeds of approximately $4.4 million for working capital and general corporate purposes, including the further development of its product candidates.

Sentiment

Score: 4

Explanation: The announcement is primarily a financial transaction, with some positive aspects related to funding future development, but also significant risks related to dilution and market impact. The sentiment is neutral to slightly negative.

Positives

• The offering aims to provide additional working capital to fund clinical programs and general corporate purposes.
• The company has the flexibility to develop its product candidates.

Negatives

• There is no guarantee that the Stockholder Approval will ever be obtained.
• The common warrants are not exercisable without Stockholder Approval and may not have any value.
• The actual combined public offering price may be at a discount to the current market price of the common stock.
• The offering may cause the trading price of the common stock to decrease.
• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• There is no public market for the common warrants or pre-funded warrants being offered.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• Investors will experience immediate and substantial dilution in the net tangible book value per share of the common stock they purchase.
• There is no public market for the common warrants or pre-funded warrants being offered.
• The common warrants are not exercisable until Stockholder Approval and may not have any value.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• Resales of our common stock in the public market during this offering by our stockholders may cause the market price of our common stock to fall.
• This offering may cause the trading price of our common stock to decrease.

Future Outlook

The company plans to initiate a dose optimization Phase 1b/2 trial in the second half of 2024, in frontline AML patients who will receive a combination of APVO436 + Venetoclax + Azacitidine to assess safety and efficacy of APVO436 and to determine an optimal dose.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Nine new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Shareholders may experience dilution.
• The company aims to fund further development of its product candidates, potentially benefiting patients.

Next Steps

• The company intends to seek Stockholder Approval for the exercise of the common warrants.
• The company plans to initiate a dose optimization Phase 1b/2 trial in the second half of 2024, in frontline AML patients who will receive a combination of APVO436 + Venetoclax + Azacitidine to assess safety and efficacy of APVO436 and to determine an optimal dose.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, Aptevo Therapeutics, capital raise, biotechnology, Roth Capital Partners, Dawson James Securities, APVO